TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31608389

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive therapy (CT)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Behavior therapy (BT)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 219
Study: 30089792

Group type: EXPERIMENTAL
Intervention: 10 g of APL daily containing 970 mg of dihydromyricetin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (10 g of APL daily without dihydromyricetin)
Number of subjects: 80
Study: 28610718

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea-derived alkylamides (Ec. extract) cream
Number of subjects: 0
Study: 25972244

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High protein expression of S6K1
Number of subjects: 0
Study: 22517610

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg loading dose)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard treatment (Control Group)
Number of subjects: 160
Study: 21435408

Group type: EXPERIMENTAL
Intervention: HIV vaccine (RV144)
Number of subjects: 16402
Study: 19380443

Group type: EXPERIMENTAL
Intervention: irinotecan (350 or 300 mg/m² every 3 weeks)
Number of subjects: 491

Group type: COMPARATOR
Intervention: FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 491
Study: 16283381

Group type: EXPERIMENTAL
Intervention: L-carnitine (3 g before each chemotherapy cycle, followed by 1 g/day for 21 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15518759

Group type: EXPERIMENTAL
Intervention: Tacrolimus + mycophenolate mofetil (MMF) (FK group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Cyclosporine + mycophenolate mofetil (MMF) (CSA group)
Number of subjects: 87
Study: 12586132

Group type: EXPERIMENTAL
Intervention: Clivarin (4200 U once daily subcutaneous)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH; 7500 anti-Xa U twice a day subcutaneous)
Number of subjects: 1200
Study: 9825354

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - 0.625 mg/day oral conjugated estrogen for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7667778

Group type: EXPERIMENTAL
Intervention: Alpha-interferon preparations injected intramuscularly in a single weekly dose of 1.10(6) ‐ 1.5.10(6) IU for courses lasting from 1 to 6 months.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional therapy for chronic persistent hepatitis B (CPHB).
Number of subjects: 37
Study: 2709521

Group type: EXPERIMENTAL
Intervention: Saphenous vein patch closure
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene patch closure
Number of subjects: 140

Group type: COMPARATOR
Intervention: Direct no‐patch closure
Number of subjects: 140
Study: 1469

Group type: EXPERIMENTAL
Intervention: Community alternative treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychiatric hospitalization
Number of subjects: 0
Study: 7022244

Group type: EXPERIMENTAL
Intervention: Pretransplantation splenectomy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) administration
Number of subjects: 50
Study: 30818971

Group type: EXPERIMENTAL
Intervention: Animal-assisted activities with dogs
Number of subjects: 47

Group type: COMPARATOR
Intervention: Novel toy and handler
Number of subjects: 47
Study: 30241318

Group type: EXPERIMENTAL
Intervention: Nordic walking training
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Supplemented group (SG)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 94
Study: 26993636

Group type: EXPERIMENTAL
Intervention: PEER-DM intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 42
Study: 25236367

Group type: EXPERIMENTAL
Intervention: Thoracoscopic wedge resection and mechanical pleurodesis (WR+MP group)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Thoracoscopic wedge resection only (WR group)
Number of subjects: 289
Study: 23170816

Group type: EXPERIMENTAL
Intervention: Online website refresher
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E-mail refresher
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Text messaging refresher
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mailed brochure (control)
Number of subjects: 0
Study: 20615852

Group type: EXPERIMENTAL
Intervention: Acupuncture as the primary intervention
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Searching Chinese language databases
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Inconclusive findings regarding acupuncture effectiveness
Number of subjects: 68
Study: 16837470

Group type: EXPERIMENTAL
Intervention: Risedronate 15 mg/day
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Risedronate 50 mg/week
Number of subjects: 1232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/day
Number of subjects: 1232
Study: 15854187

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: PIO + MET
Number of subjects: 1040
Study: 12352221

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lamivudine-famciclovir
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lamivudine-ganciclovir
Number of subjects: 12
Study: 10549062

Group type: EXPERIMENTAL
Intervention: Vectrine (erdostein), one capsule b.i.d. for 21 days
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo, one similar capsule b.i.d. for 21 days
Number of subjects: 170
Study: 7796625

Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia (St. Thomas Hospital solution) with hypothermic CPB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warm blood cardioplegia with normothermic CPB
Number of subjects: 20
Study: 2290779

Group type: EXPERIMENTAL
Intervention: Progressive relaxation training supported by temperature biofeedback for 10 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 380466

Group type: EXPERIMENTAL
Intervention: 40 mg propranolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30785826

Group type: EXPERIMENTAL
Intervention: Four cycles of epirubicin (E) 90 mg/m2 and cyclophosphamide (C) 600 mg/m2 followed by four cycles of docetaxel (T) 100 mg/m2
Number of subjects: 2449

Group type: COMPARATOR
Intervention: Six cycles of docetaxel (T) 75 mg/m2 and cyclophosphamide (C) 600 mg/m2
Number of subjects: 2449
Study: 27986874

Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 208

Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 208
Study: 25824567

Group type: EXPERIMENTAL
Intervention: Florbetaben PET imaging
Number of subjects: 216
Study: 24228862

Group type: EXPERIMENTAL
Intervention: Print-delivered basic intervention (PB)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Print-delivered environmental intervention (PE)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Web-based basic intervention (WB)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Web-based environmental intervention (WE)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 439
Study: 21864348

Group type: EXPERIMENTAL
Intervention: Eucalyptus oil and lemon tea tree oil pediculicide (EO/LTTO)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Melaleuca oil and lavender oil pediculicide (TTO/LO)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Suffocation pediculicide
Number of subjects: 92
Study: 19474053

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30-60 mg/day
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study: 17605565

Group type: EXPERIMENTAL
Intervention: Resource-oriented stress management training (Zurich resource model training)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 54
Study: 15318308

Group type: EXPERIMENTAL
Intervention: ml/kg RBW method
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ml/kg OBW method
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ICSH method
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Retzlaff's method
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ml/kg RBW and ml/kg OBW methods
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall RCM&PV measurements
Number of subjects: 120
Study: 11315840

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diet treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nondiabetic patients (control group)
Number of subjects: 20
Study: 9221965

Group type: EXPERIMENTAL
Intervention: Clozapine (150 mg/day for 31 days)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 33
Study: 8501992

Group type: EXPERIMENTAL
Intervention: Training program for community pharmacists
Number of subjects: 762
Study: 2880663

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg t.i.d.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Visacor (200 mg once daily)
Number of subjects: 24
Study: 31515083

Group type: EXPERIMENTAL
Intervention: Panitumumab treatment with early tumor shrinkage (ETS) defined as a reduction of ≥ 30% in the sum of the longest diameters of lesions at 8 weeks.
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Panitumumab treatment with depth of response (DpR) calculated as maximum percentage change in tumor size from baseline to nadir.
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Patients with symptoms at baseline who experienced ETS ≥ 30%.
Number of subjects: 659
Study: 28206871

Group type: EXPERIMENTAL
Intervention: Twice weekly progressive resistance training (PRT) and three times weekly swallowing exercises by physio- and occupational therapists, with daily home exercises throughout radiotherapy.
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 240
Study: 25985395

Group type: EXPERIMENTAL
Intervention: Pharmacist-managed medication therapy management (MTM) program administered at four visits over 6 months
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pharmacist-managed medication therapy management (MTM) program
Number of subjects: 101

Group type: COMPARATOR
Intervention: Historical control group (no specific intervention mentioned)
Number of subjects: 101
Study: 24111980

Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-160 mg/day based on weight)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Ziprasidone (in OLE)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Ziprasidone (in RCT)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo (in RCT)
Number of subjects: 237
Study: 21346105

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplementation (daily biscuit)
Number of subjects: 865
Study: 19234585

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA) supplementation in flax oil (14 g/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Resistance training (3 days a week)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 51
Study: 16492009

Group type: EXPERIMENTAL
Intervention: Social support intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12969584

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 10636263

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg for 16 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 20
Study: 8615492

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine (1/200,000)
Number of subjects: 19
Study: 1418771

Group type: COMPARATOR
Intervention: Room air exposure (0.7% carboxyhemoglobin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lower carbon monoxide exposure (3.2% carboxyhemoglobin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Higher carbon monoxide exposure (5.1% carboxyhemoglobin)
Number of subjects: 30
Study: 6386511

Group type: EXPERIMENTAL
Intervention: Enprofylline 300 mg tablets t.i.d.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Theophylline 300 mg tablets (Theo-Dur®) t.i.d.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 25
Study: 31405365

Group type: EXPERIMENTAL
Intervention: Deep tissue laser therapy (DTLT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham laser therapy (SLT)
Number of subjects: 40
Study: 30170645

Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK)
Number of subjects: 52
Study: 24490806

Group type: EXPERIMENTAL
Intervention: Taste-masked FXD-ODTs (F23) with camphor (20%, w/w) and a more hydrophilic lubricant (Pruv®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allegra® tablets (phenylalanine-containing ODT)
Number of subjects: 0
Study: 23441887

Group type: EXPERIMENTAL
Intervention: Health professional-led Chronic Disease Self-Management Support (CDSMS) programme (the Flinders Program)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CDSMS programme
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CDSMS sessions presence
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 50
Study: 20496157

Group type: EXPERIMENTAL
Intervention: Top-down costing approach
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Bottom-up costing approach
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study: 19476231

Group type: EXPERIMENTAL
Intervention: Social Cognition Training Program (including emotion recognition training and social perception training)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 14
Study: 17203353

Group type: EXPERIMENTAL
Intervention: Serenoa repens (SR) 320 mg per day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tamsulosin (TAM) 0.4 mg per day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Serenoa repens (SR) + Tamsulosin (TAM)
Number of subjects: 60
Study: 14667698

Group type: EXPERIMENTAL
Intervention: Priming with functional value of color information
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Priming with functional value of pattern information
Number of subjects: 5
Study: 11731389

Group type: EXPERIMENTAL
Intervention: Questionnaire method (parents completing a health questionnaire at age 2 years)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Routine data collection method (community clerks following children's progress)
Number of subjects: 472
Study: 7962890

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral treatment 1
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral treatment 2
Number of subjects: 2

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 2
Study: 3116609

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine‐CO2 at 36 degrees C
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine‐HCl at 36 degrees C
Number of subjects: 90
Study: 29205343

Group type: EXPERIMENTAL
Intervention: Honest, Open, Proud (HOP) program
Number of subjects: 98

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 98
Study: 27059658

Group type: EXPERIMENTAL
Intervention: Benchmarking CT dataset contouring and planning according to trial protocol
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Deviations from trial contouring protocol
Number of subjects: 33
Study: 26299563

Group type: EXPERIMENTAL
Intervention: Parent-delivered intervention
Number of subjects: 154
Study: 23553618

Group type: EXPERIMENTAL
Intervention: High hardaliye (HH) - 500 mL per day
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Low hardaliye (LH) - 250 mL per day
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group - no hardaliye
Number of subjects: 89
Study: 20537468

Group type: EXPERIMENTAL
Intervention: Early excision and skin grafting (E&G)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Delayed skin grafting
Number of subjects: 50
Study: 18779777

Group type: EXPERIMENTAL
Intervention: Adjunctive risperidone therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PaRTS‐A
Number of subjects: 0
Study: 16266782

Group type: EXPERIMENTAL
Intervention: High-level experts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-level players and nonplayers
Number of subjects: 0
Study: 12795574

Group type: EXPERIMENTAL
Intervention: Parent problem-solving (PPS) intervention
Number of subjects: 127

Group type: COMPARATOR
Intervention: Problem-solving skills training (PSST) and parent management training (PMT)
Number of subjects: 127
Study: 11201319

Group type: EXPERIMENTAL
Intervention: Insert earphones
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sound field
Number of subjects: 41
Study: 9118743

Group type: EXPERIMENTAL
Intervention: Anorectal manometry
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Endoanal sonography
Number of subjects: 152
Study: 8396956

Group type: EXPERIMENTAL
Intervention: Fragmin (KABI 2165)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fraxiparine (CY 216)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clexane (PK 10169)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Orgaran (Org 10172)
Number of subjects: 12
Study: 3080511

Group type: EXPERIMENTAL
Intervention: Astemizole (load), 30 mg once daily for 1 week and then 10 mg once daily for 1 week
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 50 mg once daily for 2 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Terfenadine, 60 mg twice daily for 2 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Astemizole (no load), 10 mg once daily for 2 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study: 31655073

Group type: EXPERIMENTAL
Intervention: Contraceptive counseling staff training intervention
Number of subjects: 756

Group type: COMPARATOR
Intervention: Usual counseling (Control)
Number of subjects: 756
Study: 29611401

Group type: EXPERIMENTAL
Intervention: LDCT‐IR
Number of subjects: 112

Group type: COMPARATOR
Intervention: SDCT
Number of subjects: 112
Study: 26816604

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.9 mg/day
Number of subjects: 360

Group type: COMPARATOR
Intervention: Additional OAD
Number of subjects: 360
Study: 24971591

Group type: EXPERIMENTAL
Intervention: Dispositional mindfulness (labeling and describing inner experiences)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dispositional mindfulness (accepting negative thoughts and feelings without judgment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychological distress
Number of subjects: 0
Study: 24573588

Group type: EXPERIMENTAL
Intervention: Subatmospheric pressure therapy (SPT)
Number of subjects: 178
Study: 19952828

Group type: EXPERIMENTAL
Intervention: Exercise group (aerobic exercise training for 4 months)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (nonexercise)
Number of subjects: 162
Study: 18215526

Group type: EXPERIMENTAL
Intervention: Auditory oddball task performed simultaneously with driving task
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Driving task performed simultaneously with auditory oddball task
Number of subjects: 20

Group type: COMPARATOR
Intervention: Driving task and secondary oddball task performed in isolation
Number of subjects: 20
Study: 15870519

Group type: EXPERIMENTAL
Intervention: Colposcopy quality control reviewers examining digitized cervical images
Number of subjects: 0
Study: 14501542

Group type: EXPERIMENTAL
Intervention: Case management intervention (n=437)
Number of subjects: 598
Study: 10541503

Group type: EXPERIMENTAL
Intervention: Chronic Helicobacter pylori infection
Number of subjects: 1122

Group type: COMPARATOR
Intervention: Age and sex matched controls
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: Sibling pairs with discordant H pylori status
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: Adjusted odds ratio after smoking and socioeconomic status
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: Adjusted odds ratio after blood lipid concentrations and obesity
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: Sibling pairs
Number of subjects: 1122
Study: 9025711

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 3 IU/m2 per day for 14 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 6 IU/m2 per day for 14 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1603479

Group type: EXPERIMENTAL
Intervention: High-dose oxytocin (6-mU/minute dosage increments)
Number of subjects: 2788
Study: 4004603

Group type: EXPERIMENTAL
Intervention: Bromocriptine (20 mg daily or less)
Number of subjects: 16
Study: 31025209

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) and fractional ablative CO2 laser (FACL) treatment (three sessions at 1-month intervals)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard moisturizers and silicone gels (control treatment)
Number of subjects: 18
Study: 29061568

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: R-CHOP plus RT
Number of subjects: 334
Study: 27393388

Group type: EXPERIMENTAL
Intervention: Interpersonal counseling
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 170

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 170
Study: 24625717

Group type: EXPERIMENTAL
Intervention: Real TMS at 110% of the estimated prefrontal cortex threshold to the left dorsolateral prefrontal cortex, 15 sessions, 325‐second trains of 10‐Hz repetitive TMS, total of 24,000 pulses
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham TMS, 15 sessions, 325‐second trains of 10‐Hz repetitive TMS, total of 24,000 pulses
Number of subjects: 68